Interleukin-33 at the maternal-fetal interface: From immune tolerance to obstetric syndromes
Journal of Reproductive Immunology · 2026
DOI: 10.1016/j.jri.2026.104855 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Reproductive Immunology, 2026. Verfasst von Tao Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances, School of Basic Medical Sciences, Guangdong Pharmaceutical University, Gu…. Hauptthemen laut MEDLINE: Interleukin-33, Immune Tolerance, Maternal-Fetal Exchange, Pre-Eclampsia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 99 Literaturangaben. Gefördert von: Guangdong Province Department of Education, Guangdong Provincial Medical Research Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Successful viviparous reproduction depends on a finely tuned state of maternal-fetal immune tolerance. Among the mediators that shape this balance, the alarmin cytokine interleukin-33 (IL-33) has drawn growing attention as a key regulatory checkpoint. Here, we bring together recent findings to interpret IL-33 function through a "Two-Wave" framework that helps reconcile its seemingly opposing roles in pregnancy. In early gestation, a controlled, spatially confined release of IL-33 appears essential for processes such as decidualization, spiral artery remodeling, and the establishment of a Type 2-biased immune environment. These effects are largely mediated through group 2 innate lymphoid cells, regulatory T cells, and M2 macrophages, which collectively sustain a tolerogenic interface. Later in pregnancy, however, an abrupt or excessive surge of IL-33-often in response to infection or tissue injury-can provoke intense inflammation. Such is now recognized as a shared pathological feature in major obstetric syndromes. In preeclampsia, excess sST2 neutralizes IL-33 activity, creating a state of functional deficiency, whereas in preterm birth, IL-33 released from fetal membranes may act as a trigger for premature labor. Given its pivotal position at the intersection of immune tolerance and inflammation, the IL-33/ST2 pathway offers both mechanistic insight and promising opportunities for biomarker development and targeted immunotherapy in complicated pregnancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances, School of Basic Medical Sciences, Guangdong Pharmaceutical University, Guangzhou 510006, China.
- Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances, School of Basic Medical Sciences, Guangdong Pharmaceutical University, Guangzhou 510006, China; School of Pharmacy, Guangdong Pharmaceutical Un…
- Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances, School of Basic Medical Sciences, Guangdong Pharmaceutical University, Guangzhou 510006, China. Electronic address: huiyin0103@gdpu.edu.cn.
Förderung
- Guangdong Province Department of Education
- Guangdong Provincial Medical Research Foundation
- National Natural Science Foundation of China
Zitieren
APA
Liu, T., Huang, H., & Yin, H. (2026). Interleukin-33 at the maternal-fetal interface: From immune tolerance to obstetric syndromes. Journal of Reproductive Immunology. https://doi.org/10.1016/j.jri.2026.104855
Vancouver
Liu T, Huang H, Yin H. Interleukin-33 at the maternal-fetal interface: From immune tolerance to obstetric syndromes. Journal of Reproductive Immunology. 2026. doi:10.1016/j.jri.2026.104855
BibTeX
@article{Liu2026,
author = {Liu, Tao and Huang, Haiqing and Yin, Hui},
title = {Interleukin-33 at the maternal-fetal interface: From immune tolerance to obstetric syndromes},
journal = {Journal of Reproductive Immunology},
year = {2026},
doi = {10.1016/j.jri.2026.104855}
}
EUVIMED